Pulsed Field Ablation Market Size, Share & Trends Analysis Report By Components (Catheters, Generators), By Indication (Atrial Fibrillation, Non Atrial Fibrillation), By End Use (Inpatient, Outpatient), By Region, And Segment Forecasts, 2025 - 2030
Pulsed Field Ablation Market Size & Trends
The global pulsed field ablation market size was estimated at USD 913.1 million in 2024 and is projected to grow at a CAGR of 33.1% from 2025 to 2030. This is driven by its promise as a safer and more effective alternative to traditional thermal ablation methods. As the global prevalence of atrial fibrillation (AF) rises, there is an increasing demand for innovative treatment options that offer fewer complications and improved outcomes. pulsed field ablation (PFA) non-thermal mechanism significantly reduces the risk of damaging surrounding tissues, a major limitation of conventional ablation techniques like radiofrequency and cryoablation. This unique advantage has led to growing interest from healthcare providers and patients, accelerating its adoption in clinical settings.
Cardiac arrhythmias, particularly atrial fibrillation (AF), are increasingly prevalent, affecting millions worldwide. AF, characterized by an irregular and often rapid heart rate, is the most common type of sustained arrhythmia, significantly raising the risk of stroke, heart failure, and other serious cardiovascular complications. As global populations age and the incidence of lifestyle-related risk factors, such as hypertension and obesity, rises, the number of AF cases continues to grow. According to the Johnson & Johnson Services, Inc. article published in February 2024, more than 37.5 million people globally live with this condition, emphasizing its widespread impact. The risk of developing AFib is notably high; statistics reveal that about one in four adults over the age of 40 experience this arrhythmia at some point in their lives. This growing prevalence highlights the urgent need for effective management and prevention strategies.
This escalating burden has created a substantial demand for effective, minimally invasive treatment options. Traditional therapies such as antiarrhythmic drugs and catheter-based ablation have limitations, leading to an unmet need for safer, more efficient approaches. The increasing prevalence of arrhythmias is thus a key driver of market growth for advanced treatment technologies like pulsed field ablation (PFA), which offer improved safety profiles and efficacy compared to conventional methods. In February 2024, an article in The Lancet Regional Health - Europe highlighted that atrial fibrillation (AF) affects 1.5-2% of European adults, expected to rise to 9.5% in those over 65 by 2060. AF is a significant risk factor for stroke, dementia, heart failure, and premature mortality, posing challenges for the aging population and healthcare systems.
Technological advancements are a key driver of the PFA industry's growth, as ongoing innovations enhance ablation procedures precision, safety, and efficacy. Leading medical device companies are investing heavily in the development of next-generation PFA systems, focusing on improving energy delivery, catheter design, and procedural efficiency. Innovations in catheter flexibility and the integration of real-time imaging and mapping technologies allow for more targeted and controlled ablation, reducing the risk of complications and improving patient outcomes. In October 2024, Abbott announced important advancements in its pulsed field ablation technologies for electrophysiology. The company finished enrolling participants in the VOLT-AF IDE Study aimed at evaluating the Volt PFA System and initiated the FOCALFLEX trial to test the TactiFlex Duo Ablation Catheter for treating paroxysmal atrial fibrillation. These initiatives mark significant progress for Abbott's PFA catheters.
Regulatory approvals are critical in influencing the PFA industry, as they validate the safety and efficacy of these novel devices, paving the way for broader clinical adoption. In recent years, several PFA systems have received CE marking in Europe, allowing them to be marketed and used across the continent. These approvals are often based on positive clinical trial results that demonstrate the benefits of PFA over traditional methods, particularly in terms of reduced procedure times and fewer complications. In October 2024, Medtronic received FDA approval for the Affera Mapping and Ablation System with Sphere-9 Catheter, designed for persistent atrial fibrillation and atrial flutter treatment. This makes Medtronic the first company with two FDA-approved pulsed-field ablation (PFA) technologies for AFib. The Sphere-9 catheter offers flexible treatment options with its 9mm lattice tip, complementing the PulseSelect PFA System, which provides a single-shot solution for pulmonary vein isolation.
Global Pulsed Field Ablation Market Report Segmentation
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global pulsed field ablation market report based on the components, indication, end use, and region.
- Components Outlook (Revenue, USD Million, 2018 - 2030)
- Catheters
- Generators
- Indication Outlook (Revenue, USD Million, 2018 - 2030)
- Atrial Fibrillation
- Non-atrial Fibrillation
- End-use Outlook (Revenue, USD Million, 2018 - 2030)
- Inpatient Facilities
- Outpatient Facilities
- Regional Outlook (Revenue, USD Million; 2018 - 2030)
- North America
- U.S.
- Canada
- Mexico
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Norway
- Denmark
- Sweden
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Please note The report will be delivered in 2-3 business days upon order notification.